Tun Aung Myint, Naing Ei Ei, Tun Nay Min, Guevara Elizabeth
Department of Internal Medicine, The Brooklyn Hospital Center, Brooklyn, New York, USA.
St George's University School of Medicine, St. George's, Grenada.
BMJ Case Rep. 2015 Sep 30;2015:bcr2015211785. doi: 10.1136/bcr-2015-211785.
It is well known that hydroxyurea can cause pancytopaenia secondary to bone marrow suppression, which is reversible with short-term discontinuation of the therapy. However, it is important to note that bone marrow suppressive effects caused by hydroxyurea could be easily potentiated in patients with sickle cell anaemia complicated by chronic kidney disease (CKD). We present a case of a Jehovah's Witness with sickle cell anaemia, who developed severe bone marrow suppression due to the combined effects of hydroxyurea and CKD, resulting in a prolonged recovery period after discontinuation of hydroxyurea.
众所周知,羟基脲可导致继发于骨髓抑制的全血细胞减少,短期停药后这种情况是可逆的。然而,需要注意的是,对于合并慢性肾脏病(CKD)的镰状细胞贫血患者,羟基脲引起的骨髓抑制作用可能很容易被增强。我们报告一例患有镰状细胞贫血的耶和华见证会信徒,该患者由于羟基脲和CKD的联合作用而出现严重的骨髓抑制,导致停用羟基脲后恢复期延长。